IMPAX Lab confirmed (in a press release Here) that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for generic versions of SOLODYN(R) (Minocycline HCI) 45mg, 90mg and 135mg Extended-release Tablets. Medicis markets SOLODYN(R) for the treatment of moderate-to-severe acne.
Friday 6 February, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment